Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  News  >  Economy & Forex

News : Latest News
Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors 
All NewsEconomyCurrencies & ForexEconomic EventsCryptocurrenciesCybersecurityPress Releases

Permira buys German specialty pharma group Neuraxpharm

share with twitter share with LinkedIn share with facebook
09/22/2020 | 01:08pm EDT

FRANKFURT, Sept 22 (Reuters) - Buyout group Permira has agreed to buy German pharma group Neuraxpharm, seeking to gain from an expected rise in demand for the company's antidepressants, painkillers and other products for the central nervous system, the companies said on Tuesday.

The deal values the company at almost 1.7 billion euros ($1.88 billion), including debt, or at about 13 times its expected 2021 core earnings, three people close to the matter said.

Permira and the seller, private equity firm Apax, declined to comment on the financial details of the deal.

The British buyout firm prevailed against competing offers from Carlyle, ICG and Goldman Sach's private equity arm, the sources said.

The runners-up also declined to comment.

Apax bought Neuraxpharm in 2016, combined it with Invent Farma, and later strengthened the company through add-on acquisitions, such as FB Health and Farmax.

The company makes specialty pharmaceuticals for neurological and psychiatric disorders, including epilepsy, Parkinson's disease, Alzheimer's disease, depression and psychosis. It has annual revenues of more than 460 million euros and 850 employees.

While global M&A activity hit its lowest level in more than a decade in the second quarter, deal-making in the healthcare sector is expected to buck the trend this year as its products and services are considered resilient to the COVID-19 crisis, investment bankers say.

Jefferies advised Apax on the deal, which Reuters flagged in July, while Rothschild advised Permira.

Jefferies is supplying a pre-arranged financing package - so-called staple financing - of more than 6.5 times core earnings, a source close to the matter said.

Apax Global Alpha, which is an investor in the Apax VIII fund selling Neuraxpharm, said the deal is expected to result in a gross multiple on invested capital of 3.5 times and a gross internal rate of return of 36%. ($1 = 0.8517 euros) (Reporting by Arno Schuetze; Editing by Michelle Adair and Barbara Lewis)

Stocks mentioned in the article
ChangeLast1st jan.
APAX GLOBAL ALPHA LIMITED -0.97% 163 Delayed Quote.-5.51%
APAX HOLDINGS -0.46% 21700 End-of-day quote.7.43%
FACEBOOK INC 2.40% 284.79 Delayed Quote.38.75%
ROTHSCHILD & CO 3.66% 24.1 Real-time Quote.-5.86%
THE CARLYLE GROUP INC. -0.72% 27.46 Delayed Quote.-14.40%
share with twitter share with LinkedIn share with facebook
Latest news "Economy & Forex"
04:36aSAMSUNG'S LEE : tainted titan who built a global tech giant
04:35aFACTBOX : Samsung's Lee leaves behind $21 billion wealth for inheritance
04:25aBANK OF ISRAEL : The Governor of the Bank of Israel announces the appointment of Uri Barazani as Bank of Israel Spokesperson
03:33aLee Kun-hee, who made South Korea's Samsung a global powerhouse, dies at 78
03:30aPCBS PALESTINIAN CENTRAL BUREAU OF STATISTICS : The Price Indices for Construction Cost, Road Cost, Water Networks Cost, Sewage Networks Cost in the West Bank, during September, 09/2020
03:23aSouth Korea President Moon to send flowers to Samsung Lee's funeral
02:46aChina's Sept soybean imports from Brazil soar 51%
02:46aTurkey extends exploration in disputed Mediterranean area to Nov. 4
02:00aCENTRAL PEOPLE GOVERNMENT OF PEOPLE RE : China's bond market sees 5.7t yuan issuance in September
12:42aLeft-leaning NDP projected to form majority British Columbia govt-CBC
Latest news "Economy & Forex"